Neuroleptic malignant syndrome (NMS) is a life threatening, though rare, complication of neuroleptic drugs. Patients suffering from this syndrome carry the A1 allele of the DRD2 gene, which is considered to reduce dopaminergic activity and glucose metabolism in regions of the brain with abundant dopamine receptors. These findings suggest the possibility that carriers of A1 show higher DRD2 blockade by neuroleptics and are more prone to develop NMS than non-carriers.
Genotype A1/A2 associated with neuroleptic malignant syndrome
DEL TACCA M;LASTELLA M;DI PAOLO, ANTONELLO;DANESI, ROMANO;MENICHETTI F;DELL'OSSO, LILIANA;
2005-01-01
Abstract
Neuroleptic malignant syndrome (NMS) is a life threatening, though rare, complication of neuroleptic drugs. Patients suffering from this syndrome carry the A1 allele of the DRD2 gene, which is considered to reduce dopaminergic activity and glucose metabolism in regions of the brain with abundant dopamine receptors. These findings suggest the possibility that carriers of A1 show higher DRD2 blockade by neuroleptics and are more prone to develop NMS than non-carriers.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
